Schlachtfest bei Medarex - 500 Beiträge pro Seite

[MR. Montana]

28$ - da brauch ich wohl nicht viel mehr zu schreiben. und das, obwohl in den letzten tagen eigentlich sogar ganz gute nachrichten kamen.

ich will nichts mehr mitbekommen, verkauft mir jemand - für mein letztes geld - ein paar geile pillen oder tripps?

ein insolventer

Mr. Montana

[defizit1]

Ist mir auch unverstaendlich - heute minus 26 % in Deutschland. Mir ist echt schlecht.
mfg
defizit1

[amnesia]

Schau dir mal CV-Therapeutics an. Minus 50%, Dagegen ist Medarex ja goldig.

[thomy18]

Medarex, Lilly and Biosite to Collaborate; Lilly Expects to Accelerate Antibody Research Through Trans-Phase Technology

PRINCETON, N.J., INDIANAPOLIS and SAN DIEGO, Jan. 4 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX), Eli Lilly and Company (NYSE: LLY) and Biosite(R) Diagnostics Incorporated (Nasdaq: BSTE) today announced a collaborative agreement under which Biosite and Medarex expect to utilize Trans-Phage Technology(SM) to generate high-affinity, fully human antibodies to genomics-derived targets provided by Lilly. In this multiyear alliance, Lilly plans to employ these antibodies in its discovery research for the purpose of identifying and validating novel targets.

Under the agreement, Lilly has agreed to provide Biosite with targets on an annual basis for a period of three years. Biosite will receive technology access fees, development fees upon delivery of a target, annual target maintenance fees, milestone fees upon the achievement of certain preclinical and clinical development milestones and royalties from products resulting from the joint research efforts. In the event antibodies developed under the collaboration progress through clinical development and commercialization, Medarex will receive license fees and milestone payments, as well as royalty payments from Lilly.

"This Lilly-Biosite-Medarex collaboration using Trans-Phage Technology is an exciting opportunity for Lilly to accelerate its therapeutic antibody research," said Thomas F. Bumol, Ph.D., Executive Director, Research Technologies and Proteins, for Lilly.

"Lilly has established one of the most extensive discovery efforts within the biotech and pharmaceutical community. We recognize Lilly`s capacity to generate significant numbers of high quality targets and value their confidence in our technology," said Gunars Valkirs, Biosite`s Vice President of Research and Development.

"We are pleased to expand our relationship with Lilly to include Trans- Phage Technology. We believe that the collaborative efforts of Lilly, Biosite and Medarex will accelerate the development of therapeutic products," said Donald L. Drakeman, President and CEO of Medarex.

In June 2000, Biosite and Medarex announced the formation of an alliance aimed at accelerating drug research via Trans-Phage Technology. This high throughput method of creating fully human antibodies combines the immunological power of Medarex`s HuMAb-Mouse(R) with the speed of Biosite`s Omniclonal(TM) phage display technology. The companies believe that the combination of Omniclonal and HuMAb-Mouse technologies enables rapid production of high-affinity antibodies with substantial diversity, which can be used to validate genomics targets and identify promising drug candidates, thereby potentially enhancing product development.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world`s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

Medarex is a biopharmaceutical company developing monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the UltiMAb(TM) Human Antibody Development System(SM) for the creation of high-affinity, fully human antibodies; T-12 Development(SM) offering the potential to move from target to trial in approximately 12 months; and Trans-Phage Technology(SM) combining high throughput screening with fully human antibody development. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex, visit its web site at www.medarex.com.

Since its inception in 1988, Biosite Diagnostics Incorporated has been dedicated to meeting important clinical needs in emergency medicine through its Triage(R) Immediate Response Diagnostics(R), which speed the flow of critical diagnostic information. In 1999, Biosite launched Biosite Discovery, a business dedicated to the collaborative discovery of novel targets and corresponding antibodies primarily in the areas of cancer, and cerebrovascular, cardiovascular and infectious diseases. The program utilizes a broad base of technologies designed to provide biotechnology and pharmaceutical customers with high throughput screening and development of high-affinity Omniclonal antibodies. Additional information on Biosite can be found at www.biosite.com.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements which are preceded by, followed by, or that include the words "believes"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in each company`s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including Eli Lilly and Company, Biosite Diagnostics Incorporated and Medarex Inc.`s Annual Reports on Form 10-K for the fiscal year ended December 31, 1999 and subsequent Forms 10- Q. Copies of each company`s respective public disclosure filings are available from each company`s investor relations department. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

Biosite(R), Immediate Response Diagnostics(R), Triage(R), Omniclonal(TM), Trans-Phage Technology(SM) and the Biosite logo are registered trademarks or service marks of Biosite Diagnostics Incorporated.

HuMAb-Mouse(R) is a registered trademark of Medarex, Inc. UltiMAb(TM) is a trademark of Medarex, Inc. Human Antibody Development System(SM), T-12 Development(SM) and Trans-Phage Technology(SM) are service marks of Medarex, Inc.


/CONTACT: Donald L. Drakeman, President and CEO of Medarex, 609-430-2880, or Kelly O`Brien of Middleberg Euro for Medarex, 212-699-2541, or [e-mail]; or Terra L. Fox, Corporate Communications of Eli Lilly, 317-276-5795, or Nadine Padilla, Director, Investor Relations and Corporate Communications of Biosite, 858-455-4808, ext. 3187, or [e-mail]/

[Jasmina6]

Mich freut es für Herrn Förtsch, der steckt doch da auch drin

[rockdj]

Ich versteh auch nix mehr: eben noch 85 Euro und 100 % plus.
Jetzt sind wir bei ca. 32 Euro / 28 USD angelangt, über 50 % verloren vom (Zwischen-)Hoch.

Schluck, Heul, Wein, Grompf, Ärger, Scheiße (...)